Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

UnitedHealth Group has named the head of its Medicare business as the CEO of its insurance business, succeeding the Brian Thompson, who was shot and killed on Dec. 4 in New York City while walking to ...

Biogen’s Spinraza (nusinersen) is another pricey option already on the market requiring injections every four months, and Roche plans a European filing of its potential rival risdiplam this year.

Regulators in the U.S. and the European Union agreed to review Biogen’s applications for approval of a higher dose Spinraza ...